Correlation of plasma trough levels of imatinib with molecular response in patients with chronic myeloid leukemia

References

• Steensma DP. The chronic myeloproliferative disorders: an historical perspective. Curr Hematol Rep 2003;2:221–230.
   PubMedGoogle Scholar
• Cortes J, Talpaz M, O’Brien S, et al. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer 2003;98:1105–1113.
   PubMed Web of Science ®Google Scholar
• Bhutani M, Vora A, Kumar L, et al. Lympho-hemopoietic malignancies in India. Med Oncol 2002;19:141–150.
   PubMed Web of Science ®Google Scholar
• Aziz Z, Iqbal J, Akram M, et al. Treatment of chronic myeloid leukemia in the imatinib era: perspective from a developing country. Cancer 2007;109:1138–1145.
   PubMed Web of Science ®Google Scholar
• Deininger MW, Druker BJ. Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev 2003;55:401–423.
   PubMed Web of Science ®Google Scholar
• Maekawa T, Ashihara E, Kimura S. The Bcr-Abl tyrosine kinase inhibitor and promising new agents against Philadelphia chromosome-positive leukemias. Int J Clin Oncol 2007;12:327–340.
   PubMed Web of Science ®Google Scholar
• Hochhaus A. Cytogenetic and molecular mechanisms of resistance to imatinib. Semin Hematol 2003;40:69–79.
   PubMed Web of Science ®Google Scholar
• Awidi A, Ayeda AO, Bsoul N, et al. Relationship of serum imatinib trough level and response in CML patients: long term follow-up. Leuk Res 2010;34:1573–1575.
   PubMed Web of Science ®Google Scholar
• Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia:a subanalysis of the IRIS study. Blood 2008;111: 4022–4028.
   PubMed Web of Science ®Google Scholar
• Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007;109:3496–3499.
   PubMed Web of Science ®Google Scholar
• Guo JQ, Lin H, Kantarjian H, et al. Comparison of competitive-nested PCR and real-time PCR in detecting BCR-ABL fusion transcripts in chronic myeloid leukemia patients. Leukemia 2002;16:2447–2453.
   PubMed Web of Science ®Google Scholar
• Velpandian T, Mathur R, Agarwal NK, et al. Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 2004;804:431–434.
   PubMed Web of Science ®Google Scholar
• Titier K, Picard S, Ducint D, et al. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2005;27:634–640.
   PubMed Web of Science ®Google Scholar
• Bakhtiar R, Khemani L, Hayes M, et al. Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2002;28:1183–1194.
   PubMed Web of Science ®Google Scholar
• Bakhtiar R, Lohne J, Ramos L, et al. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP74588) in human plasma using liquid chromatography tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci 2002;768:325–340.
   PubMed Web of Science ®Google Scholar
• Parise RA, Ramanathan RK, Hayes MJ, et al. Liquid chromato-graphic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP74588) in plasma. J Chromatogr B Anal Technol Biomed Life Sci 2003;791:39–44.
   PubMed Web of Science ®Google Scholar
• Awidi A, Salemb II, Najibb N, et al. Determination of imatinib plasma levels in patients with chronic myeloid leukemia by high performance liquid chromatography-ultraviolet detection and liquid chromatography-tandem mass spectrometry: methods’ comparison. Leuk Res 2010;34:714–717.
   PubMed Web of Science ®Google Scholar
• Pasqualotto AC, Xavier MO, Andreolla HF, et al. Voriconazole therapeutic drug monitoring: focus on safety. Expert Opin Drug Saf 2010;9:125–137.
   PubMed Web of Science ®Google Scholar
• Wojnowski L. Genetics of the variable expression of CYP3A in humans. Ther Drug Monit 2004;26:192–199.
   PubMed Web of Science ®Google Scholar
• Bolton AE, Peng B, Hubert M, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004;53:102–106.
   PubMed Web of Science ®Google Scholar
• Smith P, Bullock JM, Booker BM et al. The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy. 2004;24:1508–1514.
   PubMed Web of Science ®Google Scholar
• Frye RF, Fitzgerald SM, Lagattuta TF et al. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther. 2004;76:323–332.
   PubMed Web of Science ®Google Scholar
• Dutreix C, Peng B, Mehring G et al. Pharmacokinetic interaction between ketoconazole and Imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol. 2004;54:290–294.
   PubMed Web of Science ®Google Scholar
• Widmer N, Decosterd LA, Csajka C et al. Population pharmacokinetics of Imatinib and the role of alpha-acid glycoprotein. Br J Clin Pharmacol. 2006;62:97–112.
   PubMed Web of Science ®Google Scholar
• Gambacorti-Passerini C, Barni R, le Coutre P et al. Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000;92:1641–1650.
   PubMed Web of Science ®Google Scholar
• Crossman LC, Druker BJ, Deininger MW et al. hOCT 1 and resistance to imatinib. Blood 2005;106:1133–1134.
   PubMed Web of Science ®Google Scholar
• Wang L, Giannoudis A, Lane S et al. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008;83:258–264.
   PubMed Web of Science ®Google Scholar
• White DL, Dang P, Engler J et al. Functional activity of the OCT-1 protein is predictive of Long-Term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 2010;28:2761–2767.
   PubMed Web of Science ®Google Scholar
• White DL, Saunders VA, Dang P, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood 2007;110:4064–4072.
   PubMed Web of Science ®Google Scholar
• Widmer N, Colombo S, Buclin T, et al. Functional consequence of MDR1 expression on imatinib intracellular concentrations. Blood 2003;102:1142.
   PubMed Web of Science ®Google Scholar
• Marin D, Bazeos A, Mahon FX, et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010;28:2381–2388.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561–566.
   PubMed Web of Science ®Google Scholar
• Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005;44:879–894.
   PubMed Web of Science ®Google Scholar
• Singh N, Kumar L, Meena R, et al. Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukemia: comparing plasma levels of responders and non-responders. Eur J Clin Pharmacol 2009;65:545–549.
   PubMed Web of Science ®Google Scholar
• Ishikawa Y, Kiyoi H, Watanabe K, et al. Trough plasma concentration of imatinib reflects BCR–ABL kinase inhibitory activity and clinical response in chronic-phase chronic myeloid leukemia: a report from the BINGO study. Cancer Sci 2010;101: 2186–2192.
   PubMed Web of Science ®Google Scholar